This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.

Written by Dr. Parmis Mojarab, DO·Reviewed by Jonathan Snipes, MD·Published July 12, 2026·Last reviewed July 12, 2026·Methodology v1.0

Compounded tirzepatide: what it is, legality and safety

Quick answer

Compounded tirzepatide is the same active molecule as Mounjaro (type 2 diabetes), Zepbound (chronic weight management), prepared by a pharmacy rather than manufactured as an FDA-approved finished drug. It is not FDA-approved, the FDA does not verify its quality before marketing, and routine compounding of this molecule became restricted after the shortage resolved. Availability is a live, shifting question.

What the FDA actually saysCompounded drugs are <b>not FDA-approved</b>: the agency does not review them for safety, effectiveness or quality before they are marketed. Federal law also bars compounding drugs that are <b>essentially a copy</b> of a commercially available approved product — a bar that is lifted only while the drug is on the FDA shortage list. Both shortages are over. The FDA declared the tirzepatide shortage resolved on October 2, 2024 and the semaglutide shortage resolved on February 21, 2025, and enforcement discretion ended for all compounders between February 18 and May 22, 2025. On April 30, 2026 the FDA went further, proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list on a finding of no clinical need. Routine compounding of these molecules is therefore no longer lawful on the basis that made the market — a fact most comparison sites still describe as "permanent legitimacy." It is not.

What compounded tirzepatide is

Compounding pharmacies prepare tirzepatide in dose-flexible vials. During the brand shortage, this was a widely used, lower-cost pathway. The active ingredient is tirzepatide — the same molecule in Mounjaro (type 2 diabetes), Zepbound (chronic weight management) — but the product is not the FDA-approved finished drug.

Legality in 2026: the timeline that ended the market

The compounded GLP-1 market was built on a single legal fact: while a drug sits on the FDA shortage list, the bar against compounding an "essentially a copy" product is lifted. Both shortages are over, and the exception closed with them. Here is the exact sequence.

FDA compounding timeline for semaglutide and tirzepatide — every date sourced to an FDA order or court decision
Date	What happened	Why it matters
March 2022	Semaglutide (Wegovy) added to the FDA drug shortage list.	Shortage begins — the legal window for compounding opens.
August 2022	Ozempic (semaglutide) added to the shortage list.
December 15, 2022	Tirzepatide (Mounjaro, Zepbound) added to the shortage list.	Compounded tirzepatide becomes lawful under the shortage exception.
October 2, 2024	FDA declares the tirzepatide shortage resolved.	The legal basis for compounding tirzepatide as an 'essentially a copy' drug begins to close.
December 19, 2024	FDA reaffirms the tirzepatide resolution in a declaratory order.	Sets a 60-day (503A) / 90-day (503B) transition.
February 18, 2025	503A enforcement discretion for tirzepatide ENDS.	State-licensed pharmacies must stop compounding tirzepatide copies.
February 21, 2025	FDA removes semaglutide from the shortage list.
March 19, 2025	503B enforcement discretion for tirzepatide ENDS.	Outsourcing facilities must stop compounding tirzepatide copies.
April 22, 2025	503A enforcement discretion for semaglutide ENDS.
April 24, 2025	Court denies the Outsourcing Facilities Association's injunction (semaglutide).	OFA v. FDA, N.D. Tex. — FDA's determination stands.
May 7, 2025	Court upholds FDA on tirzepatide in OFA v. FDA.	The shortage-exception route is closed for both molecules.
May 22, 2025	503B enforcement discretion for semaglutide ENDS.	All shortage-based compounding of both molecules is now outside enforcement discretion.
April 30, 2026	FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks list.	Finding: no clinical need for outsourcing facilities to compound them from bulk. Comment period closed June 29, 2026.

The "essentially a copy" rule

Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act bar compounders from producing drugs that are essentially a copy of a commercially available FDA-approved product. While a drug sits on the FDA shortage list, that bar is lifted. Once the shortage is resolved, it snaps back.

Why every provider suddenly sells "personalized" and "microdose" doses

With the shortage exception gone, one narrow route remains open to 503A pharmacies: a compounded product is not considered 'essentially a copy' if the prescriber determines, and documents on the prescription, that the change produces a significant clinical difference for that individual patient. This is the legal mechanism — not a clinical breakthrough — behind the sudden, industry-wide appearance of "personalized dosing" and "microdose" GLP-1 programs. Changing the strength so it is not "the same, similar, or easily substitutable" as an approved dose is what keeps the product outside the copy definition.

Patients should understand what that means in practice: the dose you are offered may have been chosen partly to satisfy a regulatory test, not purely a clinical one. FDA's own guidance gives examples of a genuine clinical difference — removing an inactive ingredient because of a documented patient allergy, or switching a tablet to a liquid for a patient who cannot swallow — and expressly notes such changes are not necessarily applicable to GLP-1 drugs. That is a pointed signal about how much weight the agency gives this workaround.

Enforcement and litigation riskEli Lilly and Novo Nordisk are actively litigating against telehealth companies, medical spas and compounding pharmacies marketing compounded copies, and have sent cease-and-desist letters across the sector. Enforcement risk is not theoretical, and it falls on the provider — but a provider that is forced to stop mid-course leaves the patient without continuity of supply.

Safety: what the adverse-event data actually shows

Reported harms — FDA adverse-event dataAs of February 28, 2025, the FDA had received more than 455 adverse-event reports involving compounded semaglutide and more than 320 involving compounded tirzepatide. A recurring cause is dosing error: patients or clinicians measuring the wrong volume from a multi-dose vial, sometimes by a factor of ten. Brand auto-injectors and single-dose vials remove that failure mode; a compounded multi-dose vial reintroduces it.

Semaglutide salts are not semaglutideSome compounded products use semaglutide salts — semaglutide sodium or semaglutide acetate. These are not the same active ingredient as the semaglutide base in Wegovy and Ozempic, and the FDA has stated they are not approved for use in compounding. A program that will not state its exact salt form and concentration cannot be evaluated on safety.

Pharmacy legitimacy — a verifiable 503A or 503B license, a named prescriber, and a disclosed salt form and concentration — is the safety signal that matters. See compounded GLP-1 safety.

How to verify a program

Confirm the pharmacy is named and licensed, the prescribing clinician is named, a real medical review occurs, the salt form and concentration are disclosed, and there is no "research use only" disclaimer. Our verification checklist walks through it.

Is compounded still worth it? The price case has collapsed

The finding most comparison sites will not printThe economic case for compounded GLP-1 has narrowed sharply, and almost no comparison site says so. In 2023 the choice was roughly $1,000+/month for brand versus $150–$300 for compounded — a gap wide enough to justify real regulatory risk. As of July 12, 2026, brand Zepbound is $299–$449 through LillyDirect, brand Wegovy is $349 (or $149 for the oral tablet) through NovoCare, and both drop to roughly $25 with commercial coverage. Meanwhile compounded programs advertise $99–$299.

For a patient at a maintenance dose, the difference between a compounded program and the FDA-approved brand can now be under $150/month — and in the case of the oral Wegovy tablet at $149, brand can be cheaper than much of the compounded market. What you buy with that difference is an FDA-approved product, quality-verified before marketing, in a fixed-dose device that removes the dosing-error risk, from a supply chain that cannot be shut down mid-course by an injunction. That is a materially different trade than the one the category was built on.

Brand vs compounded — monthly cost, verified July 12, 2026

Brand figures are verified against manufacturer pricing pages. The compounded figure is the lowest advertised rate we have seen and is unverified. Note where the brand oral tablet sits.

Why we label prices instead of just listing themA caution about every compounded-price figure you will read anywhere, including on this page. Comparison sites in this category publish flatly contradictory numbers for the same providers — we have seen the same program listed at $179 on one site and $259 on another in the same month, and 'cheapest tirzepatide' claims ranging from $99 to $169 depending on who is writing. Advertised rates also frequently apply only to a first month, a starter dose, or a 12-month prepaid commitment.

We therefore label every provider price with its evidence status rather than presenting all figures as equally solid, and we treat any compounded price we have not captured ourselves as Reported, not Verified. Brand pricing on this page is verified directly against manufacturer sources, which is why we lead with it.

Frequently asked questions

Is compounded tirzepatide FDA-approved?

No. Compounded drugs are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing.

Is compounded tirzepatide still legal in 2026?

It depends on current FDA compounding rules. After the shortage resolved, routine compounding of this molecule became restricted, and the FDA proposed excluding it from the 503B bulk-substances list. Verify current status before enrolling.

Is compounded tirzepatide as safe as the brand?

We avoid the claim that compounded products 'mirror' brand safety. The molecule may be identical, but the regulatory oversight, quality verification and manufacturing controls are not.

Sources

U.S. Food and Drug Administration — Declaratory Order: Resolution of Shortage of Tirzepatide Injection Products (December 19, 2024).
U.S. Food and Drug Administration — Declaratory Order: Resolution of Shortage of Semaglutide Injection Products (February 2025).
U.S. Food and Drug Administration — "FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize."
U.S. Food and Drug Administration — Guidance: Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A.
U.S. Food and Drug Administration — Proposed exclusion of semaglutide, tirzepatide and liraglutide from the 503B bulks list (April 30, 2026).
Outsourcing Facilities Association v. FDA, N.D. Tex. (preliminary injunction denied, April 24 and May 7, 2025).
Our pharmacy-verification methodology.

Spotted an error? Submit a correction.